Assessment of tumor mutational burden through a simple blood test could help to identify which patients are most likely to benefit from immunotherapy, but optimal cutoffs are not well established.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Peters, S. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01933-w (2022).
Kasi, P. M. ASCO Daily News (October 2020); https://go.nature.com/3C2v5g3
Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. Cancer Cell 39, 154–173 (2021).
Chalmers, Z. R. et al. Genome Med. 9, 34 (2017).
Friedlaender, A. et al. Front. Oncol. 10, 142 (2020).
Strickler, J. H., Hanks, B. A. & Khasraw, M. Clin Cancer Res. 27, 1236–1241 (2021).
Chen, E. X. et al. JAMA Oncol. 6, 831–838 (2020).
Marabelle, A. et al. Lancet Oncol. 21, 1353–1365 (2020).
Malla, M., Loree, J. M., Kasi, P. M. & Parikh, A. R. J. Clin. Oncol. https://doi.org/10.1200/JCO.21.02615 (2022).
Chan, T. A. et al. Ann. Oncol. 30, 44–56 (2019).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kasi, P.M. Liquid biopsies and tumor mutational burden: the cutoff conundrum. Nat Med 28, 1753–1754 (2022). https://doi.org/10.1038/s41591-022-01999-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01999-6